Загрузка...
Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide
Carfilzomib-lenalidomide-dexamethasone (KRd) therapy has yielded promising results in patients with newly diagnosed multiple myeloma (NDMM). Cereblon (CRBN) is the direct molecular target of lenalidomide and genetic polymorphisms in CRBN have been associated with lenalidomide efficacy. In this study...
Сохранить в:
| Опубликовано в: : | Sci Rep |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Nature Publishing Group UK
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6795854/ https://ncbi.nlm.nih.gov/pubmed/31619706 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-51446-9 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|